| Literature DB >> 27247702 |
Pierpaola Davalli1, Tijana Mitic2, Andrea Caporali3, Angela Lauriola1, Domenico D'Arca4.
Abstract
The aging process worsens the human body functions at multiple levels, thus causing its gradual decrease to resist stress, damage, and disease. Besides changes in gene expression and metabolic control, the aging rate has been associated with the production of high levels of Reactive Oxygen Species (ROS) and/or Reactive Nitrosative Species (RNS). Specific increases of ROS level have been demonstrated as potentially critical for induction and maintenance of cell senescence process. Causal connection between ROS, aging, age-related pathologies, and cell senescence is studied intensely. Senescent cells have been proposed as a target for interventions to delay the aging and its related diseases or to improve the diseases treatment. Therapeutic interventions towards senescent cells might allow restoring the health and curing the diseases that share basal processes, rather than curing each disease in separate and symptomatic way. Here, we review observations on ROS ability of inducing cell senescence through novel mechanisms that underpin aging processes. Particular emphasis is addressed to the novel mechanisms of ROS involvement in epigenetic regulation of cell senescence and aging, with the aim to individuate specific pathways, which might promote healthy lifespan and improve aging.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27247702 PMCID: PMC4877482 DOI: 10.1155/2016/3565127
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Selected ROS sensitive proteins that are involved in cell signaling transduction mechanism. Indicative examples of possible effects and processes they promote after being directly and/or indirectly modified by ROS (the references are indicated inside the square brackets).
| ROS sensitive proteins: | (1) Effects of ROS sensitive proteins after being redox modified | (2) Physiopathological processes in which ROS sensitive proteins are involved |
|---|---|---|
|
| ||
| Receptor/nonreceptor tyrosine kinases | (i) Interactions between kinases pathways [ | Control of cell cycle progression [ |
| AMP-activated protein kinases | (i) Regulation of cell ROS/redox balance [ | Myocyte adaptation to energy requirement [ |
|
| ||
|
| ||
| p66Shc | (i) Signaling start in the aging process [ | Apoptosis [ |
|
| ||
|
| ||
| PPAR | (i) Redox sensor function [ | Neurodegenerative diseases [ |
|
| ||
|
| ||
| Elements in Notch1 pathway | (i) Notch signaling modulation in association with Wnt/beta-catenin signal [ | Cell fate control in vascular development [ |
|
| ||
|
| ||
| p53 | Modulation of cell redox balance (prooxidant/antioxidant effects) [ | Cell fate signaling [ |
| Nrf2 | Cell adaptation to ROS resistance [ | Apoptosis [ |
| FOXO3A | Cell coordination in response to OS [ | Metabolic adaptation to low nutrient intake [ |
| Components in | Regulation of Wnt signaling via nucleoredoxin [ | Early embryonic development [ |
| HIF-1a | Cell adaption to oxygen tension modifications [ | Cell proliferation; angiogenesis [ |
| Components in JAK–STAT pathway | (i) Cell adaption to OS [ | Stress response gene expression [ |
| NF- | Regulation of redox-sensitive gene expression | Rheumatoid arthritis, dyslipidemia, atherosclerosis, and insulin resistance [ |
Figure 1Schematic representation of ROS signaling in physiological and pathological conditions. Low and medium ROS levels produced by mitochondria and NADPH oxidase activate cell ROS sensitive proteins and epigenetic machinery. High ROS level causes nucleic acids, lipid, and proteins damage possibly involved in accelerated aging, cell death, and age-related diseases.
Clinical examples of senescence-associated biomarkers detected in organs and tissues of patients affected by age-related diseases.
| Organ/tissue | Senescence-associated biomarkers | Clinical references |
|---|---|---|
|
| ||
| Aged vascular tissues | Telomeres length, SA- | [ |
| Atherosclerosis | ||
| Systolic heart failure | ||
|
| ||
| Lung cancer | Telomeres length, SA- | [ |
| Breast cancer | SA- | [ |
| Neuroblastoma | SA- | [ |
| Astrocytoma | SA- | [ |
| Mesothelioma | SA- | [ |
| Melanoma | SA- | [ |
| Prostate cancer | SA- | [ |
| Liver cancer | Telomeres length, SA- | [ |
| Colorectal cancer | Short telomeres | [ |
|
| ||
| Idiopathic pulmonary fibrosis | Telomeres length, IGFBP5, and SA- | [ |
| Cystic fibrosis | Telomere length, p16 | [ |
| Liver fibrosis | Telomere length, IGFBP-5, SA- | [ |
| Renal fibrosis | p16 | [ |
|
| ||
| Alzheimer's disease | SA- | [ |
|
| ||
| Chronic obstructive pulmonary disease | Telomere length, p16, p21, and SA- | [ |
| Pulmonary hypertension | p16, p21 | [ |
| Emphysema | Telomere length, IGFBP-3, IGFBP-rP1, p16INK4a, and p21 | [ |
| Benign prostatic hyperplasia | SA- | [ |
Figure 2ROS-mediated senescence. Besides causing DNA damage and mitochondria dysfunction, OS activates p53 that, in turn, induces prooxidant genes and imbalances antioxidant genes induction. The set of alterations caused by ROS lead to induction of cell senescence, which, in turn, can develop both positive and negative effects; miR34a expression increases with aging in many tissues downregulating SIRT1 protein activity (a longevity promoting factor) and PNUT protein (a DNA protecting factor which prevents telomere attrition and is involved in tissues repairs).